Androgen Deprivation Therapy Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.20 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Androgen Deprivation Therapy Market Analysis
The Androgen Deprivation Therapy Market is expected to register a significant CAGR of 5.2% during the study period.
The COVID-19 pandemic significantly impacted the androgen deprivation therapy market, as cancer patients, especially prostate cancer patients, were more susceptible to coronavirus than individuals without cancer. The high susceptibility was due to the immunosuppressive state caused by malignancy and anticancer treatment. Moreover, according to the data from Cancer Treatment and Research Communications published in January 2022, it was found that during the first COVID-19 wave, there was a 17% decrease in prostate cancer diagnoses in the Netherlands. The reduction was most noticeable among older people and those with low-risk localized cancer. With the decrease in the diagnosis of cancers, the use of androgen deprivation therapy (ADT) was hampered. However, the market reached its pre-pandemic nature regarding the utilization of ADT among cancer patients, which is believed to boost the market growth in the coming years.
The key factors propelling the market growth are the rising burden of prostate cancer, increasing research and development activities, advancements in treatment technology for effective treatment of prostate cancer, rising product approvals, and strategic initiatives adopted by key market players.
Strategies such as partnerships, distribution agreements, mergers, and acquisitions adopted by key market players are expected to boost market growth. For instance, in May 2022, Myovant Sciences and Accord Healthcare, Ltd. entered into an exclusive license agreement for Accord to commercialize Relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (Relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland, and Turkey. Such partnerships will expand the accessibility of ORGOVYX across geographies, thereby leading to lucrative market growth.
Furthermore, achieving milestones in the drug development cycle will also fuel market growth. For instance, in May 2022, Bayer reported that the United States Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, limited reimbursement policies and increasing side effects are expected to hinder the market growth during the study period.
Androgen Deprivation Therapy Market Trends
Antiandrogen Sub Segment Within Drug Class Segment is Expected to Witness a Strong Growth Over the Forecast Period
Anti-androgens are drugs that connect to the androgen receptors, inhibiting the androgens from causing tumor growth. Anti-androgens are also sometimes called androgen receptor antagonists. Antiandrogens drug include Flutamide (Eulexin), Bicalutamide (Casodex), Nilutamide (Nilandron), Enzalutamide (Xtandi), apalutamide (Erleada) and darolutamide (Nubeqa).
Factors such as rising incidences of prostate cancer globally, product approvals, growing geriatric population, increasing research and development activities, and strategies adopted by key market players such as partnerships will effectively contribute to the market growth.
The growing research activities are contributing significantly to the segment's growth. For instance, in December 2021, Bayer published the results from the Phase III ARASENS trial, which investigated the use of the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide), an anti-androgen, in metastatic hormone-sensitive prostate cancer (mHSPC). The company stated that darolutamide, in combination with docetaxel and androgen deprivation therapy (ADT), significantly increased overall survival compared to docetaxel and ADT.
Additionally, in September 2021, Astellas Pharma Inc. and Pfizer Inc. stated that XTANDI (enzalutamide), an anti-androgen, improved overall survival in men with metastatic hormone-sensitive prostate cancer, which is proved through the ARCHES study. Such studies highlight anti-androgen efficacies in treating prostate cancer in terms of increased overall survival rate, which boosts anti-androgen application, driving the market.
Furthermore, in February 2021, Bayer, in partnership with Orion Corporation, expanded the global clinical development program for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in the area of prostate cancer. The company initiated a Phase III study, ARANOTE. It will evaluate the compound in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). Such strategies will allow companies to leverage others' strengths and develop an advanced product in prostate cancer, thereby leading to lucrative market growth.
Thus, due to the factors mentioned above, the studied segment is expected to contribute to the significant growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The primary driving factors for the growth of the North American androgen deprivation therapy (ADT) market are the rising prevalence of prostate cancer, the growing geriatric population, product launches, and several initiatives and investments made by key market players.
The United States within North America is expected to hold a significant share of the studied market during the study period. Prostate cancer is the most common cancer in American men. The American Cancer Society estimated that in the United States in 2023, about 288,300 new cases of prostate cancer are expected to be reported. Thus, the country's huge burden of prostate cancer is expected to increase the demand for its therapeutics. It can suppress the testosterone formed, contributing to market growth.
The above source also suggests prostate cancer is more likely to develop in older men. About 6 cases in 10 are diagnosed in men 65 or older, and it is rare in men under 40. The average age of men at diagnosis is about 66. Thereby, the growing elderly population in the region will also increase the incidence rate of prostate cancer, propelling the market.
The rising research and development studies proving the efficacies of androgen receptor inhibitors in treating pancreatic cancer will contribute to market growth. For instance, in February 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson released results from the final analysis of the Phase 3 TITAN study. It stated that ERLEADA, in combination with ADT, provided a statistically significant improvement in overall survival rate with a 35% reduction in risk of death versus ADT alone. Such technological improvement in treatment procedures is expected to drive market growth.
Additionally, in January 2021, the US FDA approved Relugolix (Orgovyx) for treating adults with prostate cancer as it is more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment, leuprolide (Lupron). Therefore, the studied market is expected to lead to lucrative growth in North America due to the abovementioned factors.
Androgen Deprivation Therapy Industry Overview
The androgen deprivation therapy market is moderately competitive. The strategies such as mergers and acquisitions and partnerships adopted by the key players will boost the market. The major players in the market are Johnson and Johnson, AstraZeneca, Bayer AG, Astellas Pharma, Tolmar Pharmaceuticals Inc., and others.
Androgen Deprivation Therapy Market Leaders
-
Johnson and Johnson
-
Astrazeneca
-
Bayer AG
-
Astellas Pharma Inc.
-
Tolmar Pharmaceuticals, Inc.
*Disclaimer: Major Players sorted in no particular order
Androgen Deprivation Therapy Market News
- March 2023: The European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- March 2023: OliX Pharmaceuticals, Inc. announced that it received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical trial of OLX72021. It is a treatment for androgenic alopecia, also known as male-pattern baldness. OLX72021 suppresses the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor.
Androgen Deprivation Therapy Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Burden of Prostrate Cancer
- 4.2.2 Rising Research and Development Activities
-
4.3 Market Restraints
- 4.3.1 Poor Reimbursement and Increasing Side Effects
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD)
-
5.1 By Treatment
- 5.1.1 By Drug Class
- 5.1.1.1 Luteinizing Hormone-Releasing Hormone (LHRH) agonists
- 5.1.1.2 Antiandrogens
- 5.1.2 By Surgery
-
5.2 By Route of Administration
- 5.2.1 Injectable
- 5.2.2 Oral
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Johnson and Johnson
- 6.1.2 Astrazeneca
- 6.1.3 Bayer AG
- 6.1.4 Astellas Pharma Inc.
- 6.1.5 AbbVie Inc.
- 6.1.6 Tolmar Pharmaceuticals, Inc.
- 6.1.7 Verity Pharmaceuticals Inc.
- 6.1.8 Foresee Pharmaceuticals Co., Ltd.
- 6.1.9 Myovant Sciences GmbH
- 6.1.10 Ferring B.V.
- 6.1.11 Viatris
- 6.1.12 Bristol-Myers Squibb Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAndrogen Deprivation Therapy Industry Segmentation
As per the scope of the report, androgen deprivation therapy is hormone therapy for prostate cancer in males by suppressing excess androgen. Androgen is a sex hormone produced in the testes and adrenalin glands in the form of testosterone and dihydrotestosterone. The Androgen Deprivation Therapy Market is segmented by treatment (drug class (Luteinizing Hormone-Releasing Hormone (LHRH) agonists and antiandrogens) and surgery), route of administration (injectable and oral), and geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Treatment | By Drug Class | Luteinizing Hormone-Releasing Hormone (LHRH) agonists |
| Antiandrogens | ||
| By Treatment | By Surgery | |
| By Route of Administration | Injectable | |
| Oral | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Androgen Deprivation Therapy Market Research FAQs
What is the current Global Androgen Deprivation Therapy Market size?
The Global Androgen Deprivation Therapy Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Global Androgen Deprivation Therapy Market?
Johnson and Johnson, Astrazeneca, Bayer AG, Astellas Pharma Inc. and Tolmar Pharmaceuticals, Inc. are the major companies operating in the Global Androgen Deprivation Therapy Market.
Which is the fastest growing region in Global Androgen Deprivation Therapy Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Androgen Deprivation Therapy Market?
In 2024, the Asia-Pacific accounts for the largest market share in Global Androgen Deprivation Therapy Market.
What years does this Global Androgen Deprivation Therapy Market cover?
The report covers the Global Androgen Deprivation Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Androgen Deprivation Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Contrast-Enhanced Ultrasound Industry Report
Statistics for the 2024 Contrast-Enhanced Ultrasound market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Contrast-Enhanced Ultrasound analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
